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 Widespread use of anticoagulant drugs for treatment and 
 prevention of thromboembolic events means it is common to 
encounter patients requiring reversal of anticoagulation for 
management of bleeding or invasive procedures. While sup-
portive and general measures apply for patients on all agents, 
recent diversifi cation in the number of licensed agents makes 
an understanding of drug-specifi c reversal strategies essen-
tial. Recognising effects upon, and limitations of, laboratory 
measures of coagulation also plays an important role. An 
understanding of reversal strategies alone is insuffi cient to 
competently care for patients who may require anticoagula-
tion reversal. It is also necessary to reduce the need for reversal 
through correct prescribing and by employing appropriate 
periprocedural bridging strategies for elective and semi-elective 
procedures. Finally, consideration of whether and when to rein-
troduce an anticoagulant drug following reversal is important 
not only to balance bleeding and thrombotic risks for individual 
patients but also for timely management of discharge. 
 Introduction 
 Since the earliest clinical investigation of heparin in the 1930s, 1 the 
indications for anticoagulant drugs and the number of commonly 
encountered agents has increased (Table  1 ). These drugs act 
by inhibiting different stages of the coagulation cascade that 
culminates in the formation of cross-linked ﬁbrin (Fig  1 ). It is common 
in clinical practice to encounter patients requiring anticoagulation 
reversal. Indications for anticoagulation reversal include: 
 > bleeding 
 > elective or emergency invasive procedures or surgery 
 > over-anticoagulation, due to accidental or intentional overdose, 
drug interactions or reduced excretion. 
 A decision to reverse anticoagulation must weigh the beneﬁts of 
anticoagulation reversal in terms of stopping bleeding or reduction 
of bleeding risk against the risk of development or extension 
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 Key points 
 The type of anticoagulant, dose, timing of last dose and 
indication are signiﬁcant points to establish when making 
decisions about anticoagulation reversal 
 For elective procedures and surgery, the need for anticoagulation 
reversal should be avoided by determining whether cessation of 
anticoagulant is required, and by following local bridging protocols 
 In patients bleeding while on anticoagulants, supportive 
treatment including blood components and local measures 
should be employed alongside the steps taken to reverse the 
anticoagulant effect 
 INR and APTT can be used to assess anticoagulant activity of 
vitamin K antagonists and unfractionated heparin respectively, 
but therapeutic ranges for these drugs cannot be used to 
interpret clotting tests in patients on other anticoagulants 
 Speciﬁc reversal agents exist for vitamin K antagonists (vitamin K 
and prothrombin complex concentrate), heparins (protamine 
sulphate) and dabigatran (Idarucizumab) but there is currently 
no speciﬁc reversal agent for fondaparinux or for the oral factor Xa 
inhibitors 
 KEYWORDS :  anticoagulants ,  direct acting oral anticoagulants , 
 reversal ,  haemorrhage ,  surgery ■ 
of thrombosis while anticoagulation is reversed. This can be 
particularly challenging in situations such as bleeding in patients 
with mechanical heart valves. 
 This article will focus on urgent reversal of anticoagulation. 
It is important that care of patients on anticoagulant drugs 
is optimised so that the need for urgent reversal is minimised. 
The beneﬁts should be weighed against a patient’s individual 
bleeding risk when deciding to anticoagulate and in choice 
of anticoagulant, and factors including potential drug–drug 
interactions and the need for dose reduction considered. 2 Anti-
platelet agents should be discontinued when an anticoagulant is 
used, except in certain circumstances. 3 An anticoagulation plan 
should be prepared in advance of elective procedures so that 
urgent reversal is not required. Table  2 summarises the length of 
time for which different anticoagulants should be stopped prior 
to an invasive procedure. Some procedures (eg joint injections, 
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endoscopic procedures with a low risk of bleeding and cataract 
surgery) can be performed without stopping anticoagulants. 
If anticoagulation is not lifelong, consideration should be given 
to deferring the procedure until treatment is completed. If 
anticoagulant treatment must be interrupted, bridging protocols 
should be employed that take into account drug pharmacokinetics 
and bleeding and the thrombotic risk. 4 
 In urgent situations where reversal is required a combination of 
general measures which apply regardless of which anticoagulant a 
patient is taking, and drug-speciﬁc management is used. Drug speciﬁc 
reversal strategies are summarised in Table  3 . General measures 
include making an assessment of the dose and timing of the drug, 
considering its rate of elimination, and in the case of bleeding 
resuscitating the patient and identifying and treating the source 
of bleeding. The efﬁcacy and evidence base for speciﬁc reversal 
strategies varies between anticoagulants, and an understanding of 
this, is important when making choices about reversal. 
 General measures for anticoagulation reversal 
 Baseline information and investigations 
 It is important to establish what anticoagulant a patient is 
taking, the dose, frequency, timing of last dose and indication. 
The anticoagulant should be stopped. Other drugs that can 
affect bleeding (eg antiplatelet agents and non-steroidal anti-
inﬂammatory drugs) should also be noted. Blood tests must 
include a full blood count and clotting screen (prothrombin time 
[PT], activated partial thromboplastin time [APTT], thrombin time 
[TT] and ﬁbrinogen). Additional clotting samples for drug-speciﬁc 
tests may be requested, guided by discussion with haematology or 
the coagulation laboratory. Liver function tests and renal function 
tests are essential to provide information on drug elimination. 
 Supportive measures 
 Bleeding patients should receive appropriate resuscitation and 
blood-component support, which in the situation of major 
haemorrhage should follow national guidelines. 5 
 Pharmacological measures 
 Tranexamic acid 1 g every 8 hours should be considered for 
patients requiring reversal of anticoagulation. Tranexamic acid is 
beneﬁcial in patients bleeding following trauma, although these 
 Table 1.  Key pharmacokinetic features of common 
anticoagulant drugs 
Name Excretion Plasma half-life 
Warfarin Hepatic metabolism to inactive 
metabolites excreted in urine
Effective half-
life 40 h
UFH Rapid endothelial cell 
internalisation (saturateable), 
slower renal clearance
45–90 min
LMWH Predominantly renal 4 h
Fondaparinux 70% renal 17–21 h
Argatroban Hepatic 45 min
Dabigatran 80% renal 13 h
Apixaban 25% renal, 75% hepatic 12 h
Edoxaban 35% renal, 65% hepatic 10–14 h
Rivaroxaban 25% renal, 75% hepatic 5–9 h
 LMWH = low-molecular-weight heparin; UFH = unfractionated heparin 
 Fig 1.  Representation of stage 
of action of anticoagulants 
and their reversal agents on a 
schematic clotting cascade. This 
diagram is intended to summarise 
drug actions but does not reﬂ ect 
the complexity of haemostasis 
believed to occur physiologi-
cally, where cell surface molecules 
regulate  initiation, ampliﬁ cation 
and propagation of thrombus. 31 
Please see the main text for details 
on speciﬁ c drug and reversal agent 
mechanisms. PCC = prothrombin 
complex concentrate; LMWH = low-
molecular-weight heparin; UFH = 
unfractionated heparin; → = promotes; 
⊥
 = suppresses 
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excretion route and elimination time (Table  1 ) suggest the 
drug has been cleared, speciﬁc reversal agents should not be 
employed. Haemodialysis and haemoﬁltration have little utility in 
anticoagulant reversal. 
 Specific management 
 Vitamin K antagonists 
 Vitamin K antagonists exert their anticoagulant effect by 
inhibiting the vitamin K dependent carboxylation of coagulation 
factors II, VII, IX and X (Fig  1 ). In the UK, warfarin is the most 
commonly prescribed vitamin K antagonist and we will focus 
on reversal of warfarin in this article. Acenocoumarol and 
phenindione may be encountered, and urgent reversal of all 
three agents follows similar principles. 8 Where cessation or dose-
reduction is insufﬁcient, reversal can be achieved with oral or 
intravenous vitamin K or by replacement of the affected factors, a 
choice determined by the desired rapidity and depth of reversal. 
 In patients with a moderately elevated international normalised 
ratio (INR) (5–8) without bleeding, reversal is usually achieved 
by withholding one or two doses of warfarin, followed by dose 
reduction. INRs above 8 confer a substantially increased bleeding 
risk so anticoagulation should be reversed with oral vitamin K 
1–5 mg. Oral vitamin K could also be considered in INRs of 5–8 
when additional bleeding risk factors are present. 9 
 Oral or intravenous vitamin K administration achieves a similar 
INR after 24 hours, but a more rapid initial effect occurs with the 
intravenous route, making it preferable in bleeding patients. 10 For 
non-major bleeding, anticoagulation reversal can be managed 
with 1–3 mg intravenous vitamin K. 9 
 In major bleeding or for emergency procedures which cannot 
be delayed until vitamin K has taken effect, rapid reversal 
of warfarin can be achieved using four-factor prothrombin 
complex concentrates (PCC) at a dose of 25–50 units/kg. These 
contain factors II, VII, IX and X and the vitamin K dependant 
anticoagulant proteins protein C and protein S. PCC containing 
lower levels of factor VII are termed three-factor PCC. They do not 
data do not relate speciﬁcally to those taking anticoagulants. 6 
It is reasonable to consider tranexamic acid for patients on 
anticoagulants with non-traumatic bleeding, provided there 
are not contraindications. Consideration of tranexamic acid 
is recommended prior to urgent surgery 4 and in adults having 
surgery who are expected to have moderate blood loss. 7 
 Local measures and intervention 
 Attempts should be made to identify the site of bleeding and 
where possible apply local measures to stop it eg pressure, 
endoscopy, surgery and interventional radiology. 
 Drug elimination 
 The extent to which an anticoagulant drug is contributing to 
bleeding or bleeding risk should be considered. If the timing, 
 Table 2.  Approximate time prior to surgery or invasive procedure for which anticoagulant drug should be 
stopped. National 4 and local guidelines and product literature should be consulted for specific details 
Drug Duration between stopping and invasive 
procedure or surgery 
 Duration before stopping and invasive procedure or surgery 
in impaired renal function – creatinine clearance <30 
 Low bleeding risk 
procedure 
High bleeding risk 
procedure 
Low bleeding risk procedure High bleeding risk procedure 
Warfarin 5 days
UFH 4 hours
LMWH Prophylactic dose, 12 hours If used, discuss dose and timing with haematology
Treatment dose, 24 hours
Fondaparinux 24–42 hours If used, discuss dose and timing with haematology
Argatroban 4 hours
Dabigatran 24 hours 48 hours Cr Cl > 50 to <80: 24–48 hours Cr Cl  > 50 to < 80: 48–72 hours
Cr Cl > 30 to <50: 48–72 hours Cr Cl  > 30 to <50: 72–96 hours
Apixaban 24 hours 48 hours 48 hours 72 hours
Edoxaban 24 hours 48 hours 48 hours 72 hours
Rivaroxaban 24 hours 48 hours 48 hours 72 hours
LMWH = low-molecular-weight heparin; UFH = unfractionated heparin
 Table 3.  Current drug-specific reversal strategies and 
novel agents under development 
Drug Drug-specific 
reversal strategy 
Agents likely to be 
available in the future 
Vitamin K 
antagonists
Vitamin K, four-factor 
PCC
Unfractionated 
heparin
Protamine sulphate Ciraparantag
Low molecular 
weight heparin
Protamine sulphate Andexanet alfa, 
Ciraparantag
Fondaparinux Consider recombinant 
activated factor VII
Andexanet alfa, 
Ciraparantag
Dabigatran Idarucizumab Ciraparantag
Factor Xa 
inhibitors
Four-factor PCC Andexanet alfa, 
Ciraparantag
 PCC = prothrombin complex concentrate 
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produce a good correction of the INR and are not recommended. 9 
PCC is superior to fresh-frozen plasma in achieving rapid correction 
of INR in patients with bleeding 11 and those requiring urgent 
warfarin reversal for surgery or procedures. 12 5 mg vitamin K 
should be given concurrently to maintain reversal when factor 
levels fall. PCCs should be avoided outside emergency situations; 
they carry risks associated with plasma-derived products (such 
as viral infection) and are associated with a risk of thrombosis. 
The limited data on thrombosis suggests the risk is relatively low 
and it is difﬁcult to distinguish from other patient risk factors. 13,14 
Nonetheless, caution is advised in patients with recent thrombosis 
or surgery, cardiovascular disease, or liver disease. 
 Unfractionated heparin 
 Unfractionated heparin (UFH) enhances the activity of 
antithrombin, an endogenous negative regulator of the clotting 
cascade that inactivates thrombin and factor Xa (Fig  1 ) as well 
as factors IXa, XIa, XIIa. UFH has a short half-life (Table  1 ) so 
rapid reversal is achievable by stopping the infusion. 15 Protamine 
sulphate is licensed for reversal of UFH, acting by preventing its 
interaction with antithrombin. Protamine sulphate is given as a 
slow intravenous bolus at a dose calculated from the number of 
units of UFH received in the last 2 hours, with 1 mg protamine 
sulphate neutralising approximately 80–100 units of UFH. In 
excess, protamine itself acts as an anticoagulant. Protamine is 
derived from ﬁsh sperm and there is a risk of allergic reactions, 
especially in individuals with previous protamine exposure, ﬁsh 
allergies and following vasectomy. 
 Low molecular weight heparin 
 Low-molecular-weight heparins (LMWH) contain shorter polymers 
than UFH, and their interaction with antithrombin affects Xa more 
than thrombin. 1 Protamine sulphate is less effective at reversing 
anti-Xa activity than antithrombin activity but is recommended 
for LMWH reversal based on an absence of alternatives and 
evidence from animal studies and small retrospective studies. 16 
Up to 8 hours from LMW heparin administration protamine 
sulphate 1 mg/100 units can be considered, with a further dose of 
0.5 mg/100 units if there is ongoing bleeding. If LMWH was given 
over 8 hours earlier, lower doses may be used. 15 
 Fondaparinux 
 Fondaparinux is a synthetic pentasaccharide not a LMWH but is 
considered here as it is used in similar indications and has a similar 
mechanism of action, by promoting the interaction of antithrombin 
and factor Xa (Fig  1 ). Protamine sulphate has no activity against 
fondaparinux. Recombinant activated factor VII can be considered 
for critical bleeding, 17 but this is an unlicensed indication. 
 Direct thrombin antagonists 
 Dabigatran and argatroban are direct thrombin antagonists. 
Dabigatran is given as an oral pro-drug dabigatran etexilate. 
Argatroban is given intravenously, its main use being in heparin-
induced thrombocytopaenia. By inhibiting thrombin these drugs 
reduce the conversion of ﬁbrinogen to ﬁbrin (Fig  1 ). Argatroban 
has a short half-life of around 45 minutes – stopping the infusion 
and initiating general measures should achieve reversal. 
 There is a licensed antidote, idarucizumab, for rapid reversal of 
dabigatran for emergency surgery and procedures or in life-
threatening or uncontrolled bleeding. It is an engineered antibody 
fragment that mimics structural features of thrombin to bind 
dabigatran with high afﬁnity, without binding other thrombin 
substrates. 18 In an open-label study, idarucizumab rapidly and 
completely reversed laboratory measures of anticoagulation in 
patients taking dabigatran. 19 
 Factor Xa inhibitors 
 Rivaroxaban, apixaban and edoxaban act by inhibiting Xa (Fig  1 ). 
Minor bleeding should be managed using local measures and 
delaying the next dose or discontinuing the drug. For more severe 
bleeding, tranexamic acid and supportive measures should be 
used but there no licensed reversal agent. For life-threatening 
bleeding PCC may be considered; 17 however, this is an unlicensed 
indication and should be discussed with a haematologist. The 
rationale is that elevation of factor levels above normal will 
promote haemostasis, but there is limited evidence to suggest an 
improvement in laboratory measures of clotting and in bleeding 
from studies in animals and healthy individuals. 20 Prospective 
cohort studies have reported effective haemostasis using PCC, 
with rates of thromboembolic complications comparable to 
patients receiving PCC for warfarin reversal. 21,22 
 What is the role of laboratory measurement? 
 Vitamin K antagonists and UFH are routinely monitored using the 
INR and APTT respectively. Anti Xa activity is a measure of LMWH 
anticoagulant effect, which may guide protamine doses. 16 
 The effect of direct thrombin antagonists and factor Xa 
inhibitors on routine clotting tests, and the utility of these tests in 
guiding reversal of anticoagulation is more complex. Therapeutic 
ranges for vitamin K antagonists and UFH should not be used 
to interpret clotting results in the presence of other agents. 
Drug-speciﬁc assays may not be available in all laboratories or 
out of hours. It is important to inform the laboratory of the type 
of anticoagulant and the timing of the last dose. The effect on 
routine clotting tests can depend upon which laboratory reagents 
are used. 23,24 Furthermore, the degree of intra-individual variation 
in drug levels (between peak and trough levels) and the degree of 
variation between individuals taking therapeutic doses must be 
taken into account when interpreting drug levels. 25 
Table  4 summarises possible interpretations of normal 
and prolonged PT, APTT and TT in the presence of thrombin 
antagonists and Xa inhibitors, and the commonest drug-speciﬁc 
assays for each agent. 
 Whether and when to restart anticoagulant drugs 
following reversal 
 The bleeding risk associated with restarting a drug must be 
balanced against the thrombotic risk while off anticoagulation. If 
haemostasis is secured following a procedure or an intervention 
for bleeding, a pragmatic approach is to restart anticoagulation 
following local bridging protocols and monitoring for further 
bleeding. 4 Often a prophylactic dose of LMWH or a direct oral 
anticoagulant (DOAC) can be started 6–8 hours post procedure. 
Decisions are more challenging following reversal for bleeding when 
no procedure to achieve haemostasis is performed, for example 
318 © Royal College of Physicians 2018. All rights reserved.
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 Table 4.  Effect of direct thrombin antagonists and Xa inhibitors on clotting tests, and drug-specific assays 
Drug PT APTT  TT  Drug specific assay 
 Normal Prolonged Normal Prolonged Normal prolonged  
Dabigatran Below or within 
therapeutic 
levels
Supra-
therapeutic 
levels
Below or within 
therapeutic 
levels
Within or above 
therapeutic 
levels
Likely little 
or no drug 
present
Cannot 
interpret
Dilute thrombin time 
or ecarin clotting 
time
Rivaroxaban Therapeutic 
levels unlikely 
but cannot be 
excluded
Therapeutic or 
supratherapeutic 
levels
Therapeutic or 
subtherapeutic 
levels
Therapeutic or 
supratherapeutic 
levels
Unaffected Rivaroxaban-specific 
anti Xa activity
Apixaban Insensitive, cannot be assessed with these methods Unaffected Apixaban-specific 
anti Xa activity
Edoxaban Therapeutic 
levels cannot 
be excluded
Not useful Unaffected Edoxaban-specific 
anti Xa activity
 APTT = activated partial thromboplastin time; PT = prothrombin time; TT = thrombin time 
in intracranial haemorrhage. For some patients, especially those 
with traumatic intracranial haemorrhage and a persistent risk of 
falls, consideration may be given to discontinuing anticoagulation. 
Data on the optimal time to reintroduce anticoagulation following 
intracranial haemorrhage is minimal and conﬂicting, with suggested 
times ranging from 4–7 days 26 to 10–30 weeks. 27 
 Future prospects 
 Two ‘universal’ reversal agents are under development. Andexanet 
alfa, recently licensed in America, is a recombinant Xa modiﬁed to 
lack catalytic and membrane-binding activity but retain afﬁnity to 
Xa inhibitors, LMWH, fondaparinux and antithrombin. 28 It corrects 
laboratory measures of coagulation in patients with major 
bleeding taking direct Xa inhibitors or the LMWH enoxaparin. 
Rates of thrombosis are higher than in studies examining PCC, 
but it is unclear to what extent this reﬂects interruption of 
anticoagulation and underlying pathology. 29 Ciraparantag is 
a synthetic molecule that binds UFH, LMWH, fondaparinux, 
Xa inhibitors and dabigatran. It has been examined in healthy 
volunteers given edoxaban where it corrected laboratory measures 
of clot formation. 30 ■
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